Australian-made device by muPharma uses ultrasound to non-invasively deliver eye therapies

MuPharma, a Melbourne-based biotech company founded by Dr. Harry Unger and Mr. Mark Unger, has developed an innovative ultrasound-based device for non-invasive delivery of therapies to ocular tissues. The handheld system, developed with engineering support from the MCN, consists of a reusable ultrasound actuator and a disposable tip with features to hold the relevant drug. The mechanism, called sonophoresis, uses gentle ultrasonic vibration to increase cell membrane permeability, allowing the drug to penetrate the tissues effectively. See link to the full article here.